By this means, PAI-1 maintained the balance of

the extracellular protein degradation and prevented the excessive degradation of ECM, thus inhibited tumor metastasis [12, 13]. In ovarian cancer cell lines, cell migratory and invasive phenotype is reduced by active PAI-1 due to its ability to inhibit plasminogen activation compared to their plasminogen activator system profiles [14]. In normal prostate epithelial cells, silencing of DLC1 by RNAi can HKI-272 purchase upregulate PAI-1 expression and reduce cell migration [15]. However, the relations between the expression of DLC1 and PAI-1 and invasion, metastasis and prognosis of epithelial ovarian carcinoma were still unknown. In this study, we detected the expression of DLC1 and PAI-1 in ovarian carcinoma, evaluated the associations between their Sorafenib concentration expressions Peptide 17 research buy and clinical pathologic factors,

and explored the role of DLC1 and PAI-1 in the prognosis of epithelial ovarian carcinoma. Material and methods Patients and tissue samples 100 ovarian specimens were obtained from the patients during surgeries in the Department of gynaecology and obstetrics, the First Affiliated Hospital of Zhengzhou University (from January 2007 to October 2010), which consisted of 25 specimens normal ovarian tissues (obtained from patients who underwent hysterectomy and oophorectomy for multiple uterinemyoma other than ovarian tumors), 75 specimens

of ovarian carcinoma tissues (contains 52 serous cystadenocarcinoma and 23 mucinous cystadenocarcinoma). Every I-II stage EOC patient underwent satisfy cytoreductive surgery, every III-IV stage EOC patient underwent unsatisfy cytoreductive surgery. The tissue samples were collected after surgery resection immediately and saved in liquid nitrogen promptly. The median age of all the patients was 52 years old (range 19 to 73). All patients did not receive preoperative radiochemotherapy. The median follow-up was 36 months (range 9 to 70 months), Olopatadine 48 patients were still survival at the end of follow-up. The tissue sample collection all obtained the consent of enrolled patients before the operation, and the present study was approved by the local Ethics Committee of Zhengzhou University. The collecting of tissue samples was supervised by a pathologist, and all the tissue samples were verified by two pathologists before IHC independently by HE stain. Immunohistochemistry The antibodies used in the Immunohistochemistry, following manufacturer’s protocols, were anti-DLC1 and anti- PAI1 (Santa Cruz, USA). Immunohistochemistry staining used DAKO EnVision System (Dako Diagnostics, Switzerland) following the protocol. For DLC1 and PAI-1 protein, staining localized in the cytoplasm was considered positive. The immunoreactive score was calculated followed Remmele’s method [16].